EcoDrugPlus

3-Hydroxy-3-Methylglutaryl-Coa Reductase

Ensembl ID : ENSSARG00000008289
Gene Symbol: HMGCR
1 External references
270 Possible Orthologues:

3-Phosphoinositide Dependent Protein Kinase 1

Ensembl ID : ENSSARG00000006013
Gene Symbol: PDPK1
1 External references
240 Possible Orthologues:

4-Hydroxyphenylpyruvate Dioxygenase

Ensembl ID : ENSSARG00000010034
Gene Symbol: HPD
1 External references
204 Possible Orthologues:

5'-Nucleotidase Ecto

Ensembl ID : ENSSARG00000005885
Gene Symbol: NT5E
1 External references
249 Possible Orthologues:

5-Hydroxytryptamine Receptor 1e

Ensembl ID : ENSSARG00000007853
Gene Symbol: HTR1E
3 External references
155 Possible Orthologues:

5-Hydroxytryptamine Receptor 1f

Ensembl ID : ENSSARG00000000710
Gene Symbol: HTR1F
1 External references
145 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSSARG00000013123
Gene Symbol: HTR2A
1 External references
218 Possible Orthologues:

5-Hydroxytryptamine Receptor 2b

Ensembl ID : ENSSARG00000000758
Gene Symbol: HTR2B
3 External references
204 Possible Orthologues:

5-Hydroxytryptamine Receptor 2c

Ensembl ID : ENSSARG00000002007
Gene Symbol: HTR2C
1 External references
224 Possible Orthologues:

5-Hydroxytryptamine Receptor 3e

Ensembl ID : ENSSARG00000003399
Gene Symbol: HTR3E
1 External references
38 Possible Orthologues:

5-Hydroxytryptamine Receptor 7

Ensembl ID : ENSSARG00000001461
Gene Symbol: HTR7
1 External references
219 Possible Orthologues:

60s Ribosomal Protein L29-Like

Ensembl ID : ENSSARG00000013572
Gene Symbol: LOC101548219
2 External references
325 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).